D-0305-2020 Class III Terminated

Recalled by Lupin Pharmaceuticals Inc. — Baltimore, MD

FDA drug recall D-0305-2020 was initiated by Lupin Pharmaceuticals Inc. on Nov 1, 2019 and is designated Class III. Reason for recall: Presence of Foreign substance: identified as a dead ant. The recall status is terminated (terminated Mar 4, 2021). Affected quantity: 30,516 bottles.

Recall details

Product Type
Drugs
Report Date
Nov 13, 2019
Initiation Date
Nov 1, 2019
Termination Date
Mar 4, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
30,516 bottles

Product description

Cefdinir for Oral Suspension USP, 250 mg/5mL,100 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, United States, Manufactured by: Lupin Limited, Mandideep 462 046 INDIA, NDC 68180-723-10

Reason for recall

Presence of Foreign substance: identified as a dead ant.

Distribution pattern

Product was distributed to major distributors/wholesalers throughout the United States.

Code information

Lot #: F802345, F802346, F802347, Exp 11/20

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0305-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0305-2020. Report a data issue: hello@regdatalab.com.